• 1.

    Dernell WSEhrhart NPStraw RC. Tumors of the skeletal system. In: Withrow SJVail DM, eds. Small animal clinical oncology. 4th ed. St Louis: Saunders, 2007;540582.

    • Search Google Scholar
    • Export Citation
  • 2.

    Mauldin GNMatus REWithrow SJ, et al. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988; 2:177180.

    • Search Google Scholar
    • Export Citation
  • 3.

    Spodnick GJBerg JRand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992; 200:995999.

    • Search Google Scholar
    • Export Citation
  • 4.

    Straw RCWithrow SJRichter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991; 5:205210.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Brodey RSAbt DA. Results of surgical treatment in 65 dogs with osteosarcoma. J Am Vet Med Assoc 1976; 168:10321035.

  • 6.

    Boston SEEhrhart NPDernell WS, et al. Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985–2004). J Am Vet Med Assoc 2006; 228:19051908.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Forrest LJDodge RKPage RL, et al. Relationship between quantitative tumor scintigraphy and time to metastasis in dogs with osteosarcoma. J Nucl Med 1992; 33:15421547.

    • Search Google Scholar
    • Export Citation
  • 8.

    Lascelles BDDernell WSCorrea MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol 2005; 12:10731083.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Bergman PJMacEwen EGKurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996; 10:7681.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Garzotto CKBerg JHoffmann WE, et al. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000; 14:587592.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Moore ASDernell WSOgilvie GK, et al. Doxorubicin and BAY 12–9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study. J Vet Intern Med 2007; 21:783790.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Mehl MLSeguin BDernell WS, et al. Survival analysis of one versus two treatments of local delivery cisplatin in a biodegradable polymer for canine osteosarcoma. Vet Comp Oncol 2005; 3:8186.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    McNeill CJOverley BShofer FS, et al. Characterization of the biological behaviour of appendicular osteosarcoma in Rottweilers and a comparison with other breeds: a review of 258 dogs*. Vet Comp Oncol 2007; 5:9098.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Bailey DErb HWilliams L, et al. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med 2003; 17:199205.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Hillers KRDernell WSLafferty MH, et al. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc 2005; 226:13641367.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Bacon NJEhrhart NPDernell WS, et al. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999–2006). J Am Vet Med Assoc 2008; 232:15041510.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Kirpensteijn JKik MRutteman G, et al. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol 2002; 39:240246.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Shapiro WFossum TWKitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988; 192:507511.

    • Search Google Scholar
    • Export Citation
  • 19.

    Thompson JPFugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). J Am Vet Med Assoc 1992; 200:531533.

    • Search Google Scholar
    • Export Citation
  • 20.

    Kraegel SAMadewell BRSimonson E, et al. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986–1989). J Am Vet Med Assoc 1991; 199:10571059.

    • Search Google Scholar
    • Export Citation
  • 21.

    Berg JWeinstein MJSchelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987–1990). J Am Vet Med Assoc 1992; 200:20052008.

    • Search Google Scholar
    • Export Citation
  • 22.

    Berg JGebhardt MCRand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997; 79:13431350.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Chun RGarrett LDHenry C, et al. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc 2005; 41:382387.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    DeRegis CJMoore ASRand WM, et al. Cisplatin and doxorubicin toxicosis in dogs with osteosarcoma. J Vet Intern Med 2003; 17:668673.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Reed E. Cisplatin, carboplatin, and oxaliplatin. In: Chabner BALongo DL, eds. Cancer chemotherapy and biotherapy principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006;332343.

    • Search Google Scholar
    • Export Citation
  • 26.

    Chun RGarrett LDVail DM. Cancer chemotherapy. In: Withrow SJVail DM, eds. Withrow and MacEwen's small animal clinical oncology. 4th ed. St Louis: Saunders Elsevier, 2007;163192.

    • Search Google Scholar
    • Export Citation
  • 27.

    Vail DMKurzman IDGlawe PC, et al. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002; 50:131136.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Khanna CPrehn JHayden D, et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 2002; 8:24062412.

    • Search Google Scholar
    • Export Citation
  • 29.

    Phillips BPowers BEDernell WS, et al. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 2009; 45:3338.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Go RSAdjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409422.

  • 31.

    Siu ILMoore MJ. Platinating agents. In: Tannock IFHill RPBristow RG, et al, eds. The basic science of oncology. 4th ed. New York: McGraw-Hill Co, 2005;322348.

    • Search Google Scholar
    • Export Citation
  • 32.

    Petrilli ASde Camargo BFilho VO, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 2006; 24:11611168.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Meyer WHPratt CBPoquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001; 19:171182.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Vail D. Veterinary Co-operative Oncology Group—common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004; 2:194213.

    • Search Google Scholar
    • Export Citation
  • 35.

    Loukopoulos PRobinson WF. Clinicopathological relevance of tumour grading in canine osteosarcoma. J Comp Pathol 2007; 136:6573.

  • 36.

    Thompson KGPool RR. Tumors of bone. In: Meuten DJ, ed. Tumors in domestic animals. 4th ed. Ames, Iowa: Iowa State Press, 2002;245317.

    • Search Google Scholar
    • Export Citation
  • 37.

    Dodd LGScully SPCothran RL, et al. Utility of fine-needle aspiration in the diagnosis of primary osteosarcoma. Diagn Cytopathol 2002; 27:350353.

  • 38.

    Domanski HAAkerman M. Fine-needle aspiration of primary osteosarcoma: a cytological-histological study. Diagn Cytopathol 2005; 32:269275.

  • 39.

    Loukopoulos PRozmanec MSutton RH. Cytological versus histopathological diagnosis in canine osteosarcoma. Vet Rec 2005; 157:784.

  • 40.

    Britt TClifford CBarger A, et al. Diagnosing appendicular osteosarcoma with ultrasound-guided fine-needle aspiration: 36 cases. J Small Anim Pract 2007; 48:145150.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Barger AGraca RBailey K, et al. Use of alkaline phosphatase staining to differentiate canine osteosarcoma from other vimentin-positive tumors. Vet Pathol 2005; 42:161165.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    Kent MSStrom ALondon CA, et al. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. J Vet Intern Med 2004; 18:540544.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Lagakos SW. The challenge of subgroup analyses—reporting without distorting. N Engl J Med 2006; 354:16671669.

  • 44.

    Bacchetta JJuillard LCochat P, et al. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol 2009; 70:3958.

  • 45.

    Ehrhart NDernell WSHoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). J Am Vet Med Assoc 1998; 213:10021006.

    • Search Google Scholar
    • Export Citation
  • 46.

    Nestor DDHolan KMJohnson CA, et al. Serum alkaline phosphatase activity in Scottish Terriers versus dogs of other breeds. J Am Vet Med Assoc 2006; 228:222224.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Page RLMcEntee MCGeorge SL, et al. Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med 1993; 7:235240.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Bailey DBRassnick KMDykes NL, et al. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors. Am J Vet Res 2009; 70:770776.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49.

    Goy-Thollot IChafotte CBesse S, et al. Iohexol plasma clearance in healthy dogs and cats. Vet Radiol Ultrasound 2006; 47:168173.

  • 50.

    Devita VTChu E. Principles of medical oncology: principles governing the use of chemotherapy. In: Devita VTLawrence TSRosenberg SA, eds. Principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2008;340.

    • Search Google Scholar
    • Export Citation
  • 51.

    Langenbach AAnderson MADambach DM, et al. Extraskeletal osteosarcomas in dogs: a retrospective study of 169 cases (1986–1996). J Am Anim Hosp Assoc 1998; 34:113120.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Kuntz CADernell WSPowers BE, et al. Extraskeletal osteosarcomas in dogs: 14 cases. J Am Anim Hosp Assoc 1998; 34:2630.

  • 53.

    Heyman SJDiefenderfer DLGoldschmidt MH, et al. Canine axial skeletal osteosarcoma. A retrospective study of 116 cases (1986 to 1989). Vet Surg 1992; 21:304310.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54.

    Straw RCPowers BEKlausner J, et al. Canine mandibular osteosarcoma: 51 cases (1980–1992). J Am Anim Hosp Assoc 1996; 32:257262.

  • 55.

    Ogilvie GKStraw RCJameson VJ, et al. Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987–1991). J Am Vet Med Assoc 1993; 202:304306.

    • Search Google Scholar
    • Export Citation
  • 56.

    Berg JWeinstein MJSpringfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995; 206:15551560.

    • Search Google Scholar
    • Export Citation

Advertisement

Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996–2006)

Dianna E. SaamMedVet Medical and Cancer Center for Pets, 300 E Wilson Bridge Rd, Worthington, OH 43085

Search for other papers by Dianna E. Saam in
Current site
Google Scholar
PubMed
Close
 DVM
,
Julius M. LiptakAlta Vista Animal Hospital, 2616 Bank St, Ottawa, ON K1T 1M9, Canada

Search for other papers by Julius M. Liptak in
Current site
Google Scholar
PubMed
Close
 BVSc, MVetClinStud, DACVS
,
Margaret J. StalkerAnimal Health Laboratory, University of Guelph, Guelph, ON N1G 2W1, Canada

Search for other papers by Margaret J. Stalker in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVP
, and
Ruthanne ChunDepartment of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI53706.

Search for other papers by Ruthanne Chun in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM

Abstract

Objective—To determine outcomes and prognostic factors for those outcomes in dogs with appendicular osteosarcoma treated with curative-intent surgery and adjuvant carboplatin.

Design—Retrospective case series.

Animals—65 client-owned dogs with appendicular osteosarcoma and no evidence of gross metastatic disease at the time of diagnosis.

Procedures—Medical records of dogs that underwent limb amputation or distal ulnectomy and adjuvant carboplatin treatment for appendicular osteosarcoma were reviewed. Adverse effects of chemotherapy and findings regarding preoperative biopsy specimens and postoperative diagnostic imaging were recorded. Signalment, clinical history, and chemotherapy variables were evaluated for associations with outcome. Histologic grade and other variables were evaluated for association with outcome for 38 tumors that were retrospectively graded.

Results—The median disease-free interval was 137 days (95% confidence interval [CI], 112 to 177 days). Median survival time was 277 days (95% CI, 203 to 355 days). The 1-, 2-, and 3-year survival rates were 36%, 22%, and 19%, respectively. None of the chemotherapy variables were associated with outcome. Preoperative proteinuria was the only clinical variable associated with poor outcome. Histologic features of tumors associated with a poor outcome were intravascular invasion, mitotic index > 5 in 3 microscopic hpfs, and grade III classification.

Conclusions and Clinical Relevance—Carboplatin administration was well tolerated and resulted in a disease-free interval and median survival time similar to those of other published protocols.

Abstract

Objective—To determine outcomes and prognostic factors for those outcomes in dogs with appendicular osteosarcoma treated with curative-intent surgery and adjuvant carboplatin.

Design—Retrospective case series.

Animals—65 client-owned dogs with appendicular osteosarcoma and no evidence of gross metastatic disease at the time of diagnosis.

Procedures—Medical records of dogs that underwent limb amputation or distal ulnectomy and adjuvant carboplatin treatment for appendicular osteosarcoma were reviewed. Adverse effects of chemotherapy and findings regarding preoperative biopsy specimens and postoperative diagnostic imaging were recorded. Signalment, clinical history, and chemotherapy variables were evaluated for associations with outcome. Histologic grade and other variables were evaluated for association with outcome for 38 tumors that were retrospectively graded.

Results—The median disease-free interval was 137 days (95% confidence interval [CI], 112 to 177 days). Median survival time was 277 days (95% CI, 203 to 355 days). The 1-, 2-, and 3-year survival rates were 36%, 22%, and 19%, respectively. None of the chemotherapy variables were associated with outcome. Preoperative proteinuria was the only clinical variable associated with poor outcome. Histologic features of tumors associated with a poor outcome were intravascular invasion, mitotic index > 5 in 3 microscopic hpfs, and grade III classification.

Conclusions and Clinical Relevance—Carboplatin administration was well tolerated and resulted in a disease-free interval and median survival time similar to those of other published protocols.

Contributor Notes

Histologic sample analysis supported by the Animal Cancer Treatment fund.

Presented in abstract form at the Veterinary Cancer Society Conference, Callaway Gardens, Ga, October 2006.

The authors thank Dr. David Vail for assistance with the statistical analysis.

Address correspondence to Dr. Saam (dsaam@medvetohio.com).